Riverdale Nursing Home: Medication Monitoring Failure NY
BRONX, NY - A state inspection at Riverdale Nursing Home revealed serious lapses in medication monitoring, with staff failing to obtain required blood tests for a resident receiving high doses of an anticonvulsant medication despite multiple reminders from pharmacy consultants.
Critical Medication Monitoring Failure Puts Resident at Risk
The facility's breakdown in basic medication safety protocols centered on Resident #39, diagnosed with Non-Alzheimer's Dementia and Schizoaffective Disorder. This resident was receiving 625 milligrams of Depakote three times daily - a substantial dose totaling 1,875 milligrams per day of this powerful anticonvulsant medication.
Despite the facility's own policies requiring physicians to "address laboratory and other diagnostic test results in a timely manner based on the resident's condition and the clinical significance of the results," staff failed to follow through on critical blood monitoring for this medication. The inspection found that although a pharmacy consultant specifically recommended obtaining serum levels on February 11, 2025, noting they were "unable to locate a recent serum level in the chart," the test was never performed.
The Nurse Practitioner documented agreement with the pharmacist's recommendation on February 12, 2025, stating "Agree Will do" and ordered the blood test for February 13. However, no evidence existed that the serum level was ever drawn, and neither the physician nor nurse practitioner followed up on the missing results.
Medical Risks of Unmonitored Depakote Administration
Depakote (valproic acid) requires careful monitoring through regular blood tests because therapeutic and toxic levels exist within a narrow range. Without proper monitoring, residents face significant health risks including liver damage, pancreatitis, and blood disorders. The medication can also cause excessive sedation, tremors, and cognitive impairment when levels become too high - particularly concerning for a resident already diagnosed with dementia.
Standard medical protocol dictates that Depakote levels should be checked within two weeks of starting the medication, then regularly thereafter - typically every six months for stable patients. The monitoring becomes even more critical when administering higher doses like the 1,875 milligrams daily this resident was receiving. Blood tests help determine whether the medication remains within the therapeutic range of 50-100 micrograms per milliliter, preventing both ineffective treatment and dangerous toxicity.
Systematic Communication Breakdown
The inspection revealed a troubling lack of accountability in the facility's medication management system. When interviewed on March 19, 2025, the Nurse Practitioner stated they "wait for the Registered Nurse to inform them of the laboratory test results" and claimed they were "not notified of the results or the reason why was the serum level not obtained."
This passive approach to critical medication monitoring directly contradicted the facility's own policies, which explicitly state that physicians must periodically review all medications and monitor for possible adverse drug reactions. The Medical Director, when interviewed the same day, acknowledged that "the Nurse Practitioner should have followed up timely when they had not received the laboratory results."
The facility's Laboratory and Diagnostic Test Results policy, revised in January 2025, clearly outlined responsibilities for processing test requisitions and reporting results. It specifically noted that concerns about test result handling "should not prevent timely, clinically appropriate management of a current result or clinical situation." Yet in this case, the absence of any follow-up mechanism allowed a critical safety test to fall through the cracks entirely.
Data source: This article is based on inspection data downloaded directly from the Centers for Medicare & Medicaid Services (CMS) via Medicare.gov. CMS releases inspection reports in bulk; we publish the findings as documented by state surveyors in the official Form CMS-2567 Statement of Deficiencies.
Plan of correction: The CMS report we receive does not include the facility's plan of correction. Facilities submit plans of correction separately to state survey agencies and those responses may not be reflected in CMS data at the time of publication. The absence of a plan of correction in our data does not mean one was not filed. Readers who want information about corrective steps taken are encouraged to contact the facility directly or their state survey agency.
Corrections may have occurred: Inspection reports reflect conditions observed on the date of the survey. Facilities may have implemented corrections, staffing changes, additional training, or other remediation since the report was issued. We report what CMS provides and encourage readers to seek current information from the facility.
Editorial process: Inspection findings are extracted from CMS source documents and synthesized using AI, reviewed for factual accuracy against the original report by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: September 19, 2026 · Our methodology
New Riverdale Rehab and Nursing in Bronx, NY was cited for violations during a health inspection on March 19, 2025.
However, **no evidence existed that the serum level was ever drawn**, and neither the physician nor nurse practitioner followed up on the missing results.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.